.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
FIDELIO-DKD evaluated the nonsteroidal mineralocorticoid receptor antagonist finerenone in people with type 2 diabetes and chronic kidney disease. Finerenone reduced the risk of kidney disease progression and cardiovascular events compared with placebo on top of optimized renin–angiotensin system blockade. The study is relevant to physicians managing diabetic CKD because residual risk persists even after blood-pressure control and ACE inhibitor or ARB therapy. Finerenone provides an additional pathway targeting mineralocorticoid receptor overactivation while generally causing less gynecomastia than steroidal MRAs. The major practical issue is hyperkalemia, so serum potassium and kidney function require monitoring before and after initiation and dose changes. In practice, therapy should be layered carefully rather than introduced without considering existing medications and electrolyte risk. The trial reinforces a broader principle: diabetic kidney disease now has several evidence-based disease-modifying options, making early identification and systematic risk stratification increasingly important.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
FIDELIO-DKD evaluated the nonsteroidal mineralocorticoid receptor antagonist finerenone in people with type 2 diabetes and chronic kidney disease. Finerenone reduced the risk of kidney disease progression and cardiovascular events compared with placebo on top of optimized renin–angiotensin system blockade. The study is relevant to physicians managing diabetic CKD because residual risk persists even after blood-pressure control and ACE inhibitor or ARB therapy. Finerenone provides an additional pathway targeting mineralocorticoid receptor overactivation while generally causing less gynecomastia than steroidal MRAs. The major practical issue is hyperkalemia, so serum potassium and kidney function require monitoring before and after initiation and dose changes. In practice, therapy should be layered carefully rather than introduced without considering existing medications and electrolyte risk. The trial reinforces a broader principle: diabetic kidney disease now has several evidence-based disease-modifying options, making early identification and systematic risk stratification increasingly important.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
